Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
Feb 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.12 - 0.34
Open     -
Vol / Avg. 0.00/42,957.00
Mkt cap 24.32M
P/E     -
Div/yield     -
EPS -0.02
Shares 131.48M
Beta 1.07
Inst. own     -

Key stats and ratios

Q3 (Jul '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -61.06% -32.18%
Return on average equity -63.70% -33.14%
CDP Score - -


700 Collip Cir Suite 114
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links


Sernova Corp. is a Canada-based clinical-stage company, which is engaged in developing products for the treatment of chronic debilitating diseases using the Cell Pouch system. The Company�s technologies include Cell Pouch System and Sertolin Technology. Cell Pouch System is implantable and scalable medical device. Sertolin technology provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets. The Company�s Cell Pouch system combined with its Sertolin immune protection technology offers therapeutic cells local protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic disease.

Officers and directors

George Adams Independent Chairman of the Board
Philip M. Toleikis President, Chief Executive Officer, Director
Cathy R. Steiner CPA Chief Financial Officer
Frank A Holler Director
Age: 57
James T. Parsons Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director